11 – 19 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2005
-
Mark
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
(
- Contribution to journal › Article
-
Mark
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
(
- Contribution to journal › Article
-
Mark
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction
(
- Contribution to journal › Article
- 2004
-
Mark
Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP
(
- Contribution to journal › Article
- 2002
-
Mark
Serum concentrations of cartilage oligomeric matrix protein, fibrinogen and hyaluronan distinguish inflammation and cartilage destruction in experimental arthritis in rats.
(
- Contribution to journal › Article
- 1999
-
Mark
A comparison of genome-scans performed in multicase families with systemic lupus erythematosus from different population groups
(
- Contribution to journal › Article
- 1981
-
Mark
Expression of major histocompatibility antigens on pancreatic islet cells
1981) In Proceedings of the National Academy of Sciences of the United States of America 78(10 I). p.6456-6460(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »